The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
|
|
|
- Timothy Robertson
- 5 years ago
- Views:
Transcription
1 The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
2 Cervix Low-grade squamous intraepithelial lesion High-grade squamous intraepithelial lesion Squamous cell carcinoma Adenocarcinoma (endocervical, usual type; mucinous; villoglandular; endometrioid; clear cell; mesonephric) Benign glandular lesions Neuroendocrine carcinoma Soft tissue tumors Melanoma Hematological malignancies Metastases
3 SIL vs. reactive Ki-67 p16: clone E6H4 Ki-67: clone MIB1 p16
4 AIS vs. hyperplasia and reactive changes Ki-67 p16: clone E6H4 Ki-67: clone MIB1 p53: clone DO-1 p16
5 Cervix adenoca. vs. SqCC vs. ASq ca. CK8: clone C51 Not useful Ber-EP4: clone Ber-EP4 CEA CK5/6: clone D5/16B4 p16 p63: clone 4A4 CK7 p40: rabbit polyclonal
6 SqCC p40 p63 CK5/6 CK8 Ber-EP4
7 Carcinoma, NOS CK8 Ber-EP4 CK5/6 p40 p63
8 Neuroendocrine carcinoma Chromogranin A Synaptophysin Synaptophysin: clone 27G12 Chromogranin A: clone MAB5268
9 Avoid CD56 CD56 CD56 HGSC
10 Clear cell carcinoma - cervix p53 mcea HNF1β Napsin p16 p16: clone E6H4 p53: clone DO-1 HNF1β: polyclonal rabbit Napsin A: clone TMU-Ad02
11 Mesonephric carcinoma EMA: clone E29 Vimentin: clone 3B4 Calretinin: clone Calret1 CD10: clone 56C6 (PAX8, TTF1, p16: +/-) (mcea, ER, PR: negative)
12 Mesonephric carcinoma EMA p16 PAX8 EMA: clone E29 Vimentin: clone 3B4 CA 125: clone M11 p16: clone E6H4 PAX8: rabbit polyclonal CA 125 Vimentin
13 Corpus uteri Adenocarcinoma (endometrioid; mucinous; clear cell, serous; neuroendocrine; mixed; undifferentiated; dedifferentiated) Carcinosarcoma Leiomyoma Sarcoma (ESS, LMS, Undifferentiated HGUS, RMS) Other soft tissue tumors (PECOMA, UTROSCAT) Trophoblastic tumors Invasion of gynecologic tumors of other origin Metastases
14 Endometrioid Serous Clear cell
15 Endometrial carcinoma Matias-Guiu and Davidson, Virchows Arch 2014;464:
16
17 Differentiating uterine AC of various histology ER: clone 6F11; positive in the majority of EC and in some SC, negative in CCC PR: clone 16; positive in the majority of EC and in some SC, negative in CCC p16: clone E6H4; patchy in EC, diffusely positive in SC, variable in CCC p53: clone DO-1; aberrant in SC + in some EC and CCC HNF1β: polyclonal rabbit; positive in CCC and some EC, usually negative in SC PTEN: clone 6H2.1; negative in majority of EC, positive in SC and CCC ARID1A: polyclonal rabbit; negative in 50% of EC and CCC, positive in SC Napsin A: clone TMU-Ad02; positive in CCC, negative in other histotypes Other: Vimentin: clone 3B4; positive in EC, variable in SC, often negative in CCC Ki-67: clone MIB1; high score in SC and CCC + in some EC mcea: clone II-7; focally positive in EC, negative in SC and CCC
18 Serous carcinoma p16 p53 p16: clone E6H4 p53: clone DO-1
19 Serous carcinoma ER p16 p53 ER: clone 6F11 p16: clone E6H4 p53: clone DO-1
20 Clear cell carcinoma HNF1β p53 p16 mcea Vimentin ER PR ER: clone 6F11 PR: clone 16 p16: clone E6H4 p53: clone DO-1 mcea: clone II-7 HNF1β: polyclonal rabbit Vimentin: clone 3B4
21 Endometrioid and clear cell carcinoma HNF1b ER PR p53 ER: clone 6F11 PR: clone 16 p53: clone DO-1 HNF1β: polyclonal rabbit
22 Endometrioid/serous carcinoma ER PR p53 p16 ER: clone 6F11 PR: clone 16 p16: clone E6H4 p53: clone DO-1
23 Serous ARID1A Endometrioid Clear cell Clear cell ARID1A: rabbit polyclonal
24 Serous PTEN Serous Endometrioid Endometrioid PTEN: clone 6H2.1
25
26
27
28 IMP2 & IMP3 IMP2 IMP2 IMP3 IMP3 IMP3 IMP3 IMP3 IMP2: rabbit polyclonal IMP3: clone N-19
29
30
31
32
33
34 Spindle cell tumor panel Actin: clone HHF35 Desmin: clone D33 SMA: 14D S100: polyclonal rabbit EMA: clone E29 Pan-cytokeratin: clone AE1/AE3 CD31: clone JC/70A CD34: QBEND-10 CD68: clone KP-1 CD99: clone EPR3097Y (rabbit)
35 Actin: clone HHF35 Desmin: clone D33 SMA: 14D h-caldesmon: clone h-cd CD10: clone 56C6 ESS vs. LMS Sub-optimal!
36 ESS vs. LMS SMA - ESS Desmin - LMS H-Caldesmon - ESS
37 ESS with sex cord pattern AE1/AE3 Vimentin Inhibin ER CD10 Pan-cytokeratin: clone AE1/AE3 Vimentin: clone 3B4 Inhibin: clone R1 ER: clone 6F11 (also clones SP1 and EP1) CD10: clone 56C6
38 CD10 ESS LMS Small cell sarcoma Small cell sarcoma
39 Potential markers? Davidson et al., Gynecol Oncol 2013;128: LMS: fatty acid binding protein-3 (FABP3), transgelin (TAGLN), neuron navigator 2 (NAV2); ESS: Cyclin D2 (CCND2), integral membrane protein 2A (ITM2A)
40 High-grade vs. low-grade ESS Cyclin D1 HG Cyclin D1 HG Cyclin D1 LG Cyclin D1: clone SP4
41 HG sarcoma with RMS areas Myf-4 Actin Desmin Myogenin Myf-4: clone LO26 Myogenin: clone F5D
42 PECOMA HMB-45 HMB-45 HMB-45: clone HMB45
43
44 Complete mole p57 p57: clone 25B2
45 Partial mole p57 p57: clone 25B2
46 Epithelioid Trophoblastic Tumor (ETT) PLAP p63 hpl p63: clone 4A4 PLAP: clone 8A9 hpl: rabbit monoclonal
47 Choriocarcinoma presenting as SqCC
48 Choriocarcinoma presenting as SqCC Pan-CK Vimentin Pan-CK: clone AE1/AE3 Vimentin: clone 3B4 HCG: rabbit polyclonal HCG
49 HCG-producing SqCC EMA CK5/6 CK8 HCG EMA: clone E29 CK5/6: clone D5/16B4 CK8: clone C51 HCG: rabbit polyclonal
50 Other
51 Melanoma Melan A: clone A103 HMB-45: clone HMB45 S100: polyclonal rabbit Vimentin: clone 3B4 Pan-cytokeratin: clone AE1/AE3
52 Melanoma HMB45 Melan A AE1/AE3 Vimentin
53 Diffuse large B-cell lymphoma CD20 CD79a MUM1 PAX5 CD20: clone L-26 CD79a: clone JCB-117 MUM1: clone MUM1p PAX5: clone 24/PAX5
54 Myelosarcoma CD15 MPO Ki-67 CD68 CD15: clone Carb-3 MPO: rabbit monoclonal Ki-67: clone MIB1 CD68: clone KP-1
55 Local extension and metastasis
56 Vaginal recurrence of endometrial carcinoma ER PR DD from primary AC in cervix ER: clone 6F11 (also clones SP1 and EP1) PR: clone 16 Vimentin: clone 3B4 mcea: clone II-7 p16: clone E6H4 HPV analysis
57 Lobular breast ca. CK8 ER PR GCDFP-15 CK8: clone C51 ER: clone 6F11 (also clones SP1 and EP1) PR: clone 16 GCDFP-15: clone 23A3
58 Appendiceal NET in cervix
59 Appendiceal NET in cervix mcea mcea CK20 Synaptophysin CDX2 Chromogranin A Synaptophysin: clone 27G12 Chromogranin A: clone MAB5268 mcea: clone II-7 CDX2: clone DAK-CDX2 CK20: clone Ks20.8
60 Urothelial carcinoma in vagina URO III CK20 CK20: clone Ks20.8 GATA3: clone L URO III: clone AU1
61 Granulosa cell tumor in vagina Inhibin Calretinin SF-1 (ovary) SF-1 (ovary) Inhibin: clone R1 Calretinin: clone Calret1 SF-1: clone 1665 (FOXL2)
62 HGSC met. to cervix WT1 ER p53 mcea WT1: clone 6F-H2 ER: clone 6F11 (also clones SP1 and EP1) p53: clone DO-1 mcea: clone II-7
63 HGSC met. to cervix Ber-EP4 WT1 WT1: clone 6F-H2 Ber-EP4: clone Ber-Ep4
64 Take-home message Morphology is the basis for diagnosis There is overlap in the immunophenotype of epithelial lesions in the cervix and corpus Metastases and rare entities should be in the differential diagnosis Molecular methods are likely to play a role in future diagnostics
65 Acknowledgements IHC lab, Oslo University Hospital Dr. Elin Borgen, MD PhD Inger Johanne Ryen, MSc
66 Thank you for your attention
Trophoblastic tumors
Trophoblastic tumors Uterus tumor course Oslo, 21-22/1/16 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Cases 45 38 39 4 Case 45
The clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Sandra Lee MD, FRCPC 1 *, Vikrant V. Sahasrabuddhe, MBBS, DrPH 2 *, Diana
05/07/2018. Types of challenges. Challenging cases in uterine pathology. Case 1 ` 65 year old female Post menopausal bleeding Uterine Polyp
Types of challenges Challenging cases in uterine pathology Nafisa Wilkinson Gynaecological Pathologist UCLH London Lack of complete history often, NO clinical history at all! Cases from other centres often
Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
Differential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
Mody. AIS vs. Invasive Adenocarcinoma of the Cervix
Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive
The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
Histopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
Reporting of carcinoma of unknown primary tumour (CUP)
Reporting of carcinoma of unknown primary tumour (CUP) Prof John Schofield Kent Oncology Centre with grateful thanks to Dr Karin Oien University of Glasgow Royal College of Pathologists Cancer datasets
ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
Dr Sanjiv Manek Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Sanjiv Manek Oxford Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust Ovarian Endometrial Vulvo-vaginal Cervical Illustration-Cellular Pathology. Oxford
Circulation: X Case number: 501 Number of responses: 84 Date: 4 MAY 12
Circulation: X Case number: 500 Number of responses: 81 Date: 4 MAY 12 Female, aged 65 TAH and BSO for G1 endometrioid adenocarcinoma. Tumour positive with inhibin, vimentin, CD56 and SMA. Negative with
Index. Cytoplasm, nonepithelial malignant tumor features 70
Accurette device 23 Adenosarcoma, differential diagnosis 80, 81 Arias-Stella reaction 65 Atypical endocervical cells 8 Atypical endometrial cells 8 Atypical glandular cells (AGC) 8, 9 Atypical glandular
Lung Tumor Cases: Common Problems and Helpful Hints
Lung Tumor Cases: Common Problems and Helpful Hints Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona Society of Pathologists
ENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS
ENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS Pacific Northwest Society of Pathologists Vancouver, B.C. September 26, 2015 Teri A. Longacre, M.D. longacre@stanford.edu Stanford University, Stanford,
NEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK UCL-Advanced Diagnostics 1st Floor, Rockefeller Building 21 University Street London WC1E 6JJ Contact: David Allen Tel: +44 (0)20 7679 6912
New Developments in Immunohistochemistry for Gynecologic Pathology
New Developments in Immunohistochemistry for Gynecologic Pathology Michael T. Deavers, M.D. Professor, Departments of Pathology and Gynecologic Oncology Immunohistochemistry in Gynecologic Pathology Majority
CASE 4 21/07/2017. Ectopic Prostatic Tissue in Cervix. Female 31. LLETZ for borderline nuclear abnormalities
Female 31 CASE 4 LLETZ for borderline nuclear abnormalities PSA Ectopic Prostatic Tissue in Cervix AJSP 2006;30;209-215 usually incidental microscopic finding usually in ectocervical stroma? developmental
Presenter: Yeh-Han Wang M.D.
Korea-Taiwan-Japan Joint Meeting for Gynecological Pathology Mini-lecture Female Adnexal Tumor of Probable Wolffian Origin (FATWO) in Taiwan: A Small Case Series and Literature Review Presenter: Yeh-Han
What I Learned from 3 Cases and 3 Antibodies
What I Learned from 3 Cases and 3 Antibodies Melinda Sanders, M.D Vanderbilt University Medical Center Professor of Pathology Consultant in Breast Pathology Disclosure of Relevant Financial Relationships
The PAX8 gene is a member of the paired-box family of
Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions Li Liang, MD, PhD; Wenxin Zheng, MD; Jinsong Liu, MD, PhD; Sharon X. Liang, MD, PhD Context. PAX8,
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS. Gabor Fischer Diagnostic Services Manitoba University of Manitoba
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS Gabor Fischer Diagnostic Services Manitoba University of Manitoba IHC INTERPRETATIONS LOCAL DATA Diagnostic Services Manitoba Number
History A 89 year old gentleman presenting with a scalp/forehead nodule. Patient had squamous cell carcinoma 18 m at same site, excised. Outside diagn
Case III History A 89 year old gentleman presenting with a scalp/forehead nodule. Patient had squamous cell carcinoma 18 m at same site, excised. Outside diagnoses: Squamous cell carcinoma. R/O: SCC, Melanoma,
Enterprise Interest None
Enterprise Interest None Invasive Stratified Mucin-producing Carcinoma (ismile) of the Cervix A Study in Morphology, Immunohistochemistry and Human Papillomavirus Status Kay J. Park, MD Memorial Sloan
When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box?
When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box? Teri A. Longacre, MD Stanford Medicine Stanford California pi6 in Gynecologic Pathology: Panacea or Pandora
IHC Panels as an Aid in Diagnostic Decision Making
IHC Antibody Test Selection Using a Panel Approach Steven Westra B.S. Reagent Product Specialist Leica Biosystems IHC Panels as an Aid in Diagnostic Decision Making Diagnostic Use of Tumors Using Algorithms
of 20 to 80 and subsequently declines [2].
![of 20 to 80 and subsequently declines [2].](/thumbs/80/81450506.jpg "of 20 to 80 and subsequently declines [2].")
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
Ovarian Clear Cell Carcinoma
Ovarian Clear Cell Carcinoma Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine 50 year old woman with chief complaint of shortness of breath
Nordic Immunohistochemical Quality Control
Nordic Immunohistochemical Quality Control Immunohistochemistry in the classifiation of neoplasias of the alimentary tract & External Quality Assurance of Immunohistochemistry for GI cancer markers Mogens
I have nothing to disclose
A 47 year old female with multiple lung nodules Disclosure of Relevant Financial Relationships Tamar Giorgadze, MD, PhD Professor of Pathology Medical College of Wisconsin Milwaukee, Wisconsin USCAP requires
Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012
Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012 These protocols were provided by customers. Under no circumstances shall Zytomed Systems
Effusion Cytology: Diagnostic Challenges
Effusion Cytology: Diagnostic Challenges Tarik M. Elsheikh, MD Professor and Medical Director, Anatomic Pathology Cleveland Clinic Outside Consult Case 45 year old woman, presented with nausea, dyspnea,
3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project
Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose any relevant financial relationship
What really matters When and Why. Pathology of Uterine Mesenchymal Lesions. Nafisa Wilkinson London
What really matters When and Why Pathology of Uterine Mesenchymal Lesions Nafisa Wilkinson London Patient centred approach immunohistochemistry Histological diagnosis Next generation sequencing Genetic
Mu ath M.A. Rjoub Supervised by: Dr. Huda Zahawi, FRCPath. King Abdullah University Hospital )KAUH(
Mu ath M.A. Rjoub Supervised by: Dr. Huda Zahawi, FRCPath. King Abdullah University Hospital )KAUH( Clinical History A 56 year old single female, presented complaining of postmenopausal bleeding. She underwent
Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors
Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors. Monophasic tumors : myoepithelioma, acinic cell carcinoma, and salivary duct carcinoma. Biphasic tumors includes
PATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.
PATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. CANCER UNKNOWN PRIMARY 3-5 % of diagnosed cancers Variability
Technology from Abcam
CD2 (EP222) CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can be found in the bone marrow. Anti-CD2 is a pan-t-cell antigen
Adenocarcinoma of the Cervix
Question 1. Each of the following statements about cervical adenocarcinoma is true except: Adenocarcinoma of the Cervix SAMS a) A majority of women with cervical adenocarcinoma have stage I tumors at diagnosis.
Current Concept in Ovarian Carcinoma: Pathology Perspectives
Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian
In situ and Invasive Endocervical Carcinoma: Problems and Pitfalls in Diagnosis
In situ and Invasive Endocervical Carcinoma: Problems and Pitfalls in Diagnosis Rouba Ali-Fehmi,MD The Karmanos Cancer Institute, Wayne State University School of Medicine Global incidence of cervical
Interesting Cases in Gynecologic Pathology. Michael Ward, MD Surgical Pathology Fellow University of Utah Health Sciences Center Salt Lake City, UT
Interesting Cases in Gynecologic Pathology Michael Ward, MD Surgical Pathology Fellow University of Utah Health Sciences Center Salt Lake City, UT Case 1 History: 50 year old woman with a uterine mass
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
CASO 1. Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.
CASO 1 Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. ASSESSMENT OF PRIMARY ORIGIN IN PATIENTS WITH A PREVIOUS HISTORY OF CANCER Primary Tumor T1 T5 T6 T13
Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of lung carcinomas and mesotheliomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Endobronchial ultrasound guided transbronchial needle biopsy
Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD
Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor
Endometrial pathology. Dr Tom Dodd and Dr Georgina England
Endometrial pathology Dr Tom Dodd and Dr Georgina England Case 1 Female age 35 Case 1 Proliferative endometrium Case 2 Female age 38 Case 2 Secretory endometrium Dating endometrium Assessed on the
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Issue No: 002 Issue date: 05 March 2018 Berkshire and Surrey Pathology Services Department of Histopathology Wexham Park Hospital Slough Berkshire
The available immunohistochemical stains and their
Immunohistochemistry in Gynecologic Pathology An Example-Based Practical Update Natalia Buza, MD; Pei Hui, MD, PhD Context. Immunohistochemical stains are routinely applied in the pathology diagnostic
Diagnostic IHC in lung and pleura pathology
Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid
TEST MENU BY SPECIALTY
1 TEST MENU BY SPECIALTY Breast Pathology Surgical excisions, needle core biopsies, and plastic surgery accepted from all sites Assessment of margins Axillary lymph node dissections Sentinel lymph nodes
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK External Quality ssessment Services for Cancer Diagnostics CIC Issue No: 005
Carcinoma of unknown primary origin (CUP) is defined
REVIEW ARTICLE Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry James R. Conner, MD, PhD and Jason L. Hornick, MD, PhD Abstract: Carcinoma of unknown primary origin
Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships
Differential of Neuroendocrine Carcinoma Alain C. Borczuk,MD Weill Cornell Medicine Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control
Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016
Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar
Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
Enterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Diagnoses one would not like to miss in soft tissue pathology early in your career Marta Sbaraglia, MD Department of Pathology Hospital of Treviso University of Padua
Diagnostically Challenging Cases in Gynecologic Pathology
Diagnostically Challenging Cases in Gynecologic Pathology Eric C. Huang, M.D., Ph.D. Department of Pathology and Laboratory Medicine University of California, Davis Medical Center Case 1 Presentation 38
Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Laboratory Contact: Breege Nicholson Queen Elizabeth Hospital Tel: +44 (0) 208 333 3000 ext. 8478 Stadium Road E-Mail:
What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden
What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden Maastricht Pathology 2018 Wednesday 20 th June Endometrioid adenocarcinoma High grade carcinomas (common)
ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome
Hereditary Ovarian and Breast Cancer Syndrome C. Blake Gilks, MD Dept of Pathology Vancouver General Hospital University of British Columbia Blake.gilks@vch.ca The USCAP requires that anyone in a position
Ascitic Fluid and Use of Immunocytochemistry. Mercè Jordà, University of Miami
Ascitic Fluid and Use of Immunocytochemistry Mercè Jordà, University of Miami Is It Malignant? Yes? No Ascitic Fluid Cytomorphologic Useful Findings Tight clusters with smooth borders Cellular and nuclear
Case 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:
Case 18 M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is: A. Pilomatrical carcinoma B. Adnexal carcinoma NOS C. Metastatic squamous cell carcinoma D.Primary squamous cell carcinoma
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
2018 ICD-O-3 Updates in Table Format with Annotation for Reference
Status Histology Description (this may be preferred term or a synonym) Report Comments New term 8010 3 Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term 8013 3 Combined large cell neuroendocrine
Impact of immunostaining of pulmonary and mediastinal cytology
Impact of immunostaining of pulmonary and mediastinal cytology Harman Sekhon MD, PhD Director of Cytopathology Head of Ottawa-site Ontario Tumour Bank June 20, 2014 Disclaimer Pfizer: Honorarium-Advisory
Endometrial Stromal Tumors
Endometrial Stromal Tumors WHO Categories: Endometrial Stromal Nodule (ESN) Endometrial Stromal Sarcoma, low grade (LGESS) Endometrial Stromal Sarcoma, high grade (HGESS) Undifferentiated Uterine Sarcoma
Ovarian carcinoma classification. Robert A. Soslow, MD
Ovarian carcinoma classification Robert A. Soslow, MD soslowr@mskcc.org WHO classification Serous Mucinous Endometrioid Clear cell Transitional Squamous Mixed epithelial Undifferentiated Introduction Rationale
Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment
Reprinted by permission of UK NEQAS Immunocytochemistry and David S. Gray Kind thanks to David S. Gray for allowing ThermoFisher Scientific, Lab Vision Products, to distribute this article. Immunocytochemistry
Scotland and Northern Ireland EQA Scheme. Circulation 46
Scotland and Northern Ireland EQA Scheme Circulation 46 Special Educational Cases E1 and E2 Presented by Dr K Robertson Case E1 Female 42 year old with heavy menstrual and intermenstrual bleeding. IUS
Intravascular Endometrium Mimicking Vascular Invasion
ISPUB.COM The Internet Journal of Pathology Volume 12 Number 1 A Papanicolau, G Lin Citation A Papanicolau, G Lin.. The Internet Journal of Pathology. 2010 Volume 12 Number 1. Abstract Intravascular endometrium
Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia
Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Sílvia Bagué Servei de Patologia Hospital de Sant Pau Barcelona Soft tissue sarcomas Heterogeneous group
64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus
Case 6 64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus Numerous irregular, large glands with leaf-like pattern Large glands with broad-based papillary infolding into the
In Situ Hybridization Immunohistochemistry
2013-2014 In Situ Hybridization Immunohistochemistry A History of Delivering Superior Products Genemed Biotechnologies, Inc. was founded in 1987 and is located in the center of the South San Francisco
Classification (1) Classification (3) Classification (2) Spindle cell lesions. Spindle cell lesions of bladder (Mills et al.
Non-epithelial tumours and nonepithelial tumour-like lesions of the bladder Dr Jonathan H Shanks The Christie NHS Foundation Trust, Manchester, UK Classification (1) Myofibroblastic proliferations and
Type I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53
Type I Excess estrogen Lynch Endometrioid adenocarcinoma PTEN Type II High grade More aggressive Serous, Clear Cell p53 Stage I IA IB Stage II Stage III IIIA IIIB IIIC IIIC1 IIIC2 Stage IV IVA IVB nodes
2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:
E-Path A.I. Engine Knowledge Base Enhancements Version 1.0.0.29 April 1, 2018 The major enhancements in the E-Path Knowledge Base from versions 1.0.0.28 through 1.0.0.29 are as follows: 1. Addition/modification
Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3
Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9)
Mesothelioma Pathobasic. Lukas Bubendorf Pathology
Mesothelioma Pathobasic Lukas Bubendorf Pathology Mechanisms of Asbestos Carcinogenesis in Mesothelioma Asprin High-mobility group protein B1 master switch HMGB1 Initiation/ perpetuation of inflamm. response
Cytology and Surgical Pathology of Gynecologic Neoplasms
Cytology and Surgical Pathology of Gynecologic Neoplasms Current Clinical Pathology ANTONIO GIORDANO, MD, PHD SERIES EDITOR For further titles published in this series, go to http://www.springer.com/springer/series/7632
Case Report Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report
Int J Clin Exp Pathol 2012;5(1):77-82 www.ijcep.com /ISSN: 1936-2625/IJCEP1111016 Case Report Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report Yan Shen
Carcinoma of Unknown Primary (CUP)
Metasta c Carcinoma of Unknown Primary: Diagnos c Approach Using Immunohistochemistry James R. Conner, MD, PhD Mount Sinai Hospital Toronto, ON Carcinoma of Unknown Primary (CUP) 3-5% of all new malignant
Neuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:
H&N Neuroendocrine Neoplasms: Classification and Diagnostic Considerations Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Broad Classification: A. Epithelial:
Serous effusion Objectives. Cytology of Serous Effusions From basics to challenges
Cytology of Serous Effusions From basics to challenges Cytology of Serous Effusions From basics to challenges Pınar Fırat, MD, MIAC Department of Pathology, İstanbul University, İstanbul Faculty of Medicine,
Urinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
Financial disclosures
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchc Geisel School of
In the past several years, significant progress has been
Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers A Review and Update Kai Zhang, MD; Hongbin Deng, MD, PhD; Philip T. Cagle, MD Context. Immunohistochemistry has
Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases
International Journal of Research in Medical Sciences Patel A et al. Int J Res Med Sci. 2015 Dec;3(12):3833-3839 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20151452
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources 1 IHC Identification Targets Specimens Controls 2 Tissue controls Trouble Spots 3 The Key to Description IHC Description 4 Intermediate Filaments
Enterprise Interest No disclosures.
Enterprise Interest No disclosures. Secondary Tumours in Uropathology Case 2 PRESENTED AT: EUROPEAN CONGRESS OF PATHOLOGY 18 #ECP2018 Slides are the property of the author. Permission required for reuse.
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY
CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY Jason L Hornick, MD, PhD Director of Surgical Pathology Director of Immunohistochemistry Brigham and Women s Hospital Associate